STOCK TITAN

Ra Medical’s Electrophysiology Division Announces First Hospital to Complete 100 Procedures Using the VIVO System

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Positive)
Tags
Rhea-AI Summary
Ra Medical Systems' subsidiary, Catheter Precision, achieves milestone with 100 ventricular ablation procedures completed using VIVO imaging system
Positive
  • Catheter Precision's subsidiary completes 100 ventricular ablation procedures using VIVO imaging system
  • Hospital's use of VIVO demonstrates recognition of its benefits and success of utilization strategies
  • VIVO improves workflow and chances of successful ablation for patients
Negative
  • None.

FORT MILL, SC / ACCESSWIRE / June 12, 2023 / Ra Medical Systems, Inc. (RMED:NYSE/American) announced today that its wholly owned subsidiary, Catheter Precision, Inc., has had its first customer, Heart Hospital of New Mexico at Lovelace Medical Center, complete 100 ventricular ablation procedures with the assistance of VIVO, a non-invasive 3D imaging system that identifies the earliest electrical activation of a ventricular arrhythmia.

"This is a significant milestone for Catheter Precision", said David Jenkins, interim CEO. "We continue to believe that physicians and hospitals will find value using VIVO and to see a hospital use it this much in a relatively short period of time demonstrates that the benefits of VIVO are being recognized and that our utilization strategies are working."

VIVO is used to assist physicians in physicians in pre-procedure planning for ventricular ablations. When used in advance of the procedure, VIVO can provide additional information to the physician about the patient's heart to streamline what are often long and complicated procedures lasting 4-5 hours.

Dr Sean Mazer, MD, clinical Electrophysiologist at the Heart Hospital of New Mexico and president of the New Mexico Heart Institute/Lovelace Medical Group says, "We have implemented VIVO in all of our PVC ablations. It has helped speed up and improve the workflow for our most difficult procedures. It has also improved the chances of successful ablation for the patients. Some of these arrhythmias were not treatable without VIVO."

Catheter Precision recently built out a direct sales team in early 2023 to expand upon the successful, but limited launch and to expand its footprint across the United States.

About VIVO

Catheter Precision's VIVO™ (View Into Ventricular Onset), is a non-invasive 3D imaging system that enables physicians to identify the origin of ventricular arrhythmias pre-procedure, thereby streamlining workflow and reducing procedure time. VIVO has received marketing clearance from the U.S. FDA and has the CE mark.

About Ra Medical Systems

Ra Medical, and its wholly owned subsidiary Catheter Precision, is an innovative U.S.-based medical device company bringing new solutions to market to improve the treatment of cardiac arrhythmias. It is focused on developing groundbreaking technology for electrophysiology procedures by collaborating with physicians and continuously advancing its products.

CONTACTS:

At the Company
David Jenkins
973-691-2000
mhuck@catheterprecision.com

SOURCE: Ra Medical Systems



View source version on accesswire.com:
https://www.accesswire.com/760298/Ra-Medicals-Electrophysiology-Division-Announces-First-Hospital-to-Complete-100-Procedures-Using-the-VIVO-System

FAQ

Who completed 100 ventricular ablation procedures using VIVO imaging system?

Heart Hospital of New Mexico at Lovelace Medical Center

What is VIVO?

VIVO is a non-invasive 3D imaging system that identifies the earliest electrical activation of a ventricular arrhythmia.

What are the benefits of VIVO?

VIVO provides additional information to physicians for pre-procedure planning, streamlines procedures, and improves chances of successful ablation.

What is the significance of this milestone for Catheter Precision?

It demonstrates recognition of the benefits of VIVO and the success of utilization strategies.

What is Catheter Precision's plan for expansion?

They have built out a direct sales team in early 2023 to expand their footprint across the United States.

Ra Medical Systems, Inc.

NYSE:RMED

RMED Rankings

RMED Latest News

RMED Stock Data

3.84M
4.60M
36.85%
11%
1.26%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
US
Carlsbad

About RMED

advanced excimer laser-based vascular and dermatological therapies we are a commercial-stage medical device company leveraging our advanced excimer laser-based platform for use in the treatment of vascular and dermatological diseases. we believe our products enhance patients’ quality of life by restoring blood-flow in arteries and clearing chronic skin conditions. we currently manufacture and market two lines of products: dabra catheter and laser is cleared by the u.s. fda as a tool for the minimally invasive endovascular treatment of vascular blockages resulting from lower extremity vascular disease, which includes peripheral artery disease (pad), which commonly occurs in the legs. pharos excimer laser pharos is designed for use in the treatment of inflammatory skin conditions and is fda cleared as a tool used in the treatment of psoriasis, atopic dermatitis, and leukoderma. our goal is to become the leading medical device company marketing excimer lasers as tools for the treatment of